Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1401-1410 of 9367

Page
per page
  1. CGP 57380
    B3570 CGP 57380
    Target: MNK
    Summary: MNK1 inhibitor, specific and selective
      insoluble in EtOH; insoluble in H2O; ≥12.2 mg/mL
  2. L-Mimosine
    B4751 L-Mimosine
    Target: Hydroxylases
    Summary: iron chelator and prolyl 4-hydroxylase inhibitor
      insoluble in DMSO; insoluble in EtOH; ≥1.98 mg/mL
  3. FPH2 (BRD-9424)
    B4753 FPH2 (BRD-9424)
     1 Citation
    Summary: inducer of proliferation of primary human hepatocytes
      ≥35.4 mg/mL
  4. LDC000067
    B4754 LDC000067
     2 Citation
    Target: Cyclin-Dependent Kinases
    Summary: CDK9 inhibitor, novel and highly specific
      insoluble in H2O; insoluble in EtOH; ≥18.52 mg/mL
  5. PI-1840
    B4755 PI-1840
    Summary: Chymotrypsin-like (CT-L) inhibitor
  6. YH239-EE
    B4756 YH239-EE
    Summary: p53-MDM2 antagonist, potent
      ≥50.4 mg/mL
  7. INH6
    B4757 INH6
    Summary: Hec1/Nek2 inhibitor, potent
      ≥32.2 mg/mL
  8. GS-9973
    B3553 GS-9973
    Target: Syk
    Summary: Syk inhibitor, orally bioavailable and selective
      insoluble in EtOH; insoluble in H2O; ≥20.55 mg/mL
  9. BAPTA-AM
    B4758 BAPTA-AM
     12 Citation
    Target: Calcium chelator
    Summary: BAPTA-AM
      insoluble in H2O; insoluble in EtOH; ≥16.3 mg/mL
  10. Raltegravir potassium salt
    B4760 Raltegravir potassium salt
    Summary: HIV integrase inhibitor
      ≥13.53 mg/mL

Items 1401-1410 of 9367

Page
per page